Skip to main content
APLM
NASDAQ Life Sciences

Apollomics Faces Nasdaq Delisting Risk, Terminates $3.8M Licensing Deal

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$20.5
Mkt Cap
$45.019M
52W Low
$3.659
52W High
$42.12
52W Position info
460% above low
Off High info
51% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

APLM has more than doubled off its 52-week low of $3.659.

Summary

Apollomics Inc. received a Nasdaq delisting notice for low market value and terminated a licensing agreement due to a partner's failure to pay $3.8 million, regaining rights to its lead asset.


Key Events · Legal and Risk Events · APLM

  • Nasdaq Delisting Notice Received

    Apollomics Inc. received a notice from Nasdaq for non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company has 180 calendar days, until December 15, 2026, to regain compliance by maintaining an MVLS above $35 million for at least 10 consecutive business days.

  • Material Licensing Agreement Terminated

    The company terminated its Collaboration and License Agreement with Launxp International Co., Ltd. due to Launxp's failure to remit a $3.8 million upfront payment balance. Apollomics has initiated a dispute resolution process to recover the unpaid amount and has regained global rights (outside Mainland China and Macau) to its lead clinical asset, vebreltinib (APL-101).


Analysis · APLM · Life Sciences

Apollomics Inc. received a Nasdaq notice for failing to meet the minimum Market Value of Listed Securities, initiating a 180-day compliance period to avoid potential delisting. This is a significant risk to the company's public trading status. Concurrently, the company terminated a collaboration agreement with Launxp International Co., Ltd. due to an unpaid $3.8 million balance. While Apollomics regains global rights to its lead asset, vebreltinib, the immediate loss of this substantial payment, especially following a recent 'going concern' disclosure, further strains the company's financial position.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APLM was trading at $20.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45M. The 52-week trading range was $3.66 to $42.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APLM - Latest Insights

APLM
Nov 09, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.25
Real-time Price: $17.68 info
Change: -$0.570 (-3%) info
Market Cap: $51.537M info
APLM
Nov 06, 2026, 4:15 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $19.00
Real-time Price: $17.68 info
Change: -$1.32 (-7%) info
Market Cap: $51.537M info
APLM
Aug 17, 2026, 7:23 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $23.55
Real-time Price: $17.68 info
Change: -$5.87 (-25%) info
Market Cap: $51.537M info
APLM
Aug 17, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.55
Real-time Price: $17.68 info
Change: -$5.87 (-25%) info
Market Cap: $51.537M info
APLM
Aug 11, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $17.68 info
Change: -$0.480 (-3%) info
Market Cap: $51.537M info